QURE
QURE clinical trials: uniQure N.V.
Every trial on ClinicalTrials.gov where uniQure N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 8
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
QURE on the catalyst calendar · QURE registry changes
- Primary completion Dec 30, 2030Sponsor estimatePhase 1/Phase 2NCT06100276Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1...UniQure Biopharma B.V. · Amyotrophic Lateral SclerosisActive, not recruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2027Sponsor estimatePhase 1/Phase 2NCT06270316Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry DiseaseUniQure Biopharma B.V. · Fabry DiseaseRecruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06063850AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyUniQure Biopharma B.V. · Mesial Temporal Lobe EpilepsyRecruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 1/Phase 2NCT04120493Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's DiseaseUniQure Biopharma B.V. · Huntington's DiseaseActive, not recruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1/Phase 2NCT05243017Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's DiseaseUniQure Biopharma B.V. · Huntington DiseaseActive, not recruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2023ActualNo phase registeredNCT03293810Glybera Registry, Lipoprotein Lipase Deficient (LPLD) PatientsUniQure Biopharma B.V. · Lipoprotein Lipase DeficiencyCompletedQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2019ActualPhase 1/Phase 2NCT03300453Intracerebral Gene Therapy in Children With Sanfilippo Type B SyndromeUniQure Biopharma B.V. · Sanfilippo Syndrome BCompletedQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2020Sponsor estimatePhase 2NCT02904772Alipogene Tiparvovec for the Treatment of LPLD PatientsUniQure Biopharma B.V. · LPL DeficiencyWithdrawnQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2023ActualNo phase registeredNCT04723680An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their FamiliesHaemnet · HemophiliaCompletedQURECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 1NCT02082860Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaDigna Biotech S.L. · Acute Intermittent PorphyriaCompletedQURECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2013ActualNo phase registeredNCT02076763Observational Study of Acute Intermittent Porphyria PatientsDigna Biotech S.L. · Acute Intermittent PorphyriaCompletedQURECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner